We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
-0.92%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$313M
AUM Growth
+$43.7M
Cap. Flow
+$70.4M
Cap. Flow %
22.5%
Top 10 Hldgs %
58.61%
Holding
92
New
33
Increased
17
Reduced
11
Closed
31

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$26.8M
2
DXCM icon
DexCom
DXCM
+$24.3M
3
ABBV icon
AbbVie
ABBV
+$21.2M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$20.1M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$14.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$25.5M
2
JNJ icon
Johnson & Johnson
JNJ
+$21.1M
3
MDT icon
Medtronic
MDT
+$14.2M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$9.82M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.66M

Sector Composition

Rank Sector Weight
1 Healthcare 92.58%
2 Industrials 0.23%
3 Financials 0.16%
4 Technology 0.14%
5 Energy 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMGN icon
1
Amgen
AMGN
$198B
$28.9M 9.24%
+107,480
New +$26.8M
TEVA icon
2
Teva Pharmaceuticals
TEVA
$37.2B
$26.9M 8.59%
2,632,893
+1,527,123
+138% +$14.2M
DXCM icon
3
DexCom
DXCM
$29.5B
$24.9M 7.98%
267,380
+215,582
+416% +$24.3M
ABBV icon
4
AbbVie
ABBV
$451B
$21.5M 6.89%
+144,561
New +$21.2M
SPY icon
5
State Street SPDR S&P 500 ETF Trust
SPY
$785B
$19.3M 6.18%
+45,208
New +$20.1M
REGN icon
6
Regeneron Pharmaceuticals
REGN
$70.5B
$16.5M 5.27%
20,009
-635
-3% -$499K
CTLT
7
DELISTED
CATALENT, INC.
CTLT
$13M 4.16%
285,999
+85,002
+42% +$3.97M
NTRA icon
8
Natera
NTRA
$38.9B
$12.2M 3.89%
274,795
+221,831
+419% +$11.3M
AVDL
9
DELISTED
Avadel Pharmaceuticals
AVDL
$10.1M 3.24%
983,602
-55,872
-5% -$748K
AXSM icon
10
Axsome Therapeutics
AXSM
$11.9B
$9.96M 3.18%
142,510
-57,570
-29% -$4.3M
GEHC icon
11
GE HealthCare
GEHC
$28.6B
$8.97M 2.87%
+131,810
New +$9.59M
WST icon
12
West Pharmaceutical
WST
$25.4B
$8.42M 2.69%
22,454
-18,104
-45% -$7M
PRAX icon
13
Praxis Precision Medicines
PRAX
$8.75B
$8.3M 2.65%
323,719
-1,922
-0.6% -$36.4K
SILK
14
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$8.04M 2.57%
536,392
+337,860
+170% +$7.03M
ARGX icon
15
argenx
ARGX
$53.9B
$7.05M 2.26%
+14,346
New +$7.02M
XFOR icon
16
X4 Pharmaceuticals
XFOR
$360M
$6.81M 2.18%
208,250
+71,585
+52% +$3.12M
IMGN
17
DELISTED
Immunogen Inc
IMGN
$5.87M 1.88%
369,912
+72,105
+24% +$1.2M
XENE icon
18
Xenon Pharmaceuticals
XENE
$6.56B
$5.87M 1.88%
171,755
+147,534
+609% +$5.52M
ARCT icon
19
Arcturus Therapeutics
ARCT
$168M
$5.34M 1.71%
+208,886
New +$6.43M
NUVL
20
DELISTED
Nuvalent
NUVL
$5.22M 1.67%
+113,528
New +$5.04M
VRNA
21
DELISTED
Verona Pharma
VRNA
$5.18M 1.66%
318,076
+166,882
+110% +$3.21M
AMLX icon
22
Amylyx Pharmaceuticals
AMLX
$2B
$5.18M 1.66%
+282,862
New +$5.98M
PMVP icon
23
PMV Pharmaceuticals
PMVP
$68.8M
$5.04M 1.61%
821,384
+662,971
+419% +$4.56M
MDGL icon
24
Madrigal Pharmaceuticals
MDGL
$12.7B
$4.93M 1.58%
33,761
+7,751
+30% +$1.46M
ATXS
25
DELISTED
Astria Therapeutics
ATXS
$4.46M 1.43%
598,128
+374,054
+167% +$3.19M
1
2 3 4

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
LS
Leelyn Smith Geneva, Illinois $713M AUM 17.46% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return

Tri Locum Partners's Q3 2023 Portfolio in Review

As of Q3 2023, Tri Locum Partners held 92 positions worth $313M, up 16% from $269M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Tri Locum Partners deployed $70.4M of net new capital in Q3 2023, opening 33 new positions and adding to 17 existing holdings. Its largest new stake was Amgen: 107,480 shares worth $28.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 99% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was West Pharmaceutical, an estimated $7M trimmed.

  • Tri Locum Partners's largest Q3 2023 buy was Amgen: 107,480 shares worth $28.9M.
  • Tri Locum Partners added most to DexCom in Q3 2023, an estimated $24.3M increase.
  • Tri Locum Partners's biggest Q3 2023 reduction was West Pharmaceutical, cutting an estimated $7M.
  • Tri Locum Partners fully exited Eli Lilly in Q3 2023, selling an estimated $25.5M.
  • Tri Locum Partners's ten largest holdings make up 59% of its $313M portfolio in Q3 2023.
  • Tri Locum Partners opened 33 new positions and closed 31 in Q3 2023.
  • Tri Locum Partners's portfolio value rose 16% quarter-over-quarter to $313M.

Based on Tri Locum Partners's 13F filing for Q3 2023, filed 14 Nov 2023.